ZTS
Zoetis Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
78.80
close · 2026-10-29
value
36
cheaper than peers36
quality
64
stronger fundamentals64
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 9.25× | 69 |
| forward P/E | 12.24× | 42 |
| price to sales | 3.25× | 36 |
| price to book | 10.37× | 21 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 64.9% | 96 |
| operating margin | 40.7% | 89 |
| revenue growth | -0.2% | 31 |
| debt to equity | 294.0% | 19 |
4 of 4 measures available
Facts
| market cap | $33B |
| free cash flow | $2.02B |
| employees | 14,500 |
| first trade | 2013-02-01 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 6.02 | 5.47 | 5.07 | 4.49 |
| free cash flow | $2.28B | $2.30B | $1.62B | $1.33B |
| net income | $2.67B | $2.49B | $2.34B | $2.11B |
| revenue | $9.47B | $9.26B | $8.54B | $8.08B |
| unusual items | -$104.0M | -$141.0M | -$34.0M | -$119.0M |